Predicting medical prognosis in patients with glioblastoma during inpatient rehabilitation using bed mobility function.

The study used a single-site convenience sample, so it may not represent other populations. Because it was retrospective, data were extracted from records and manual review could introduce selection bias or errors. The analysis did not account for comorbidities, extent of resection, radiation dose changes, or tumor-treating fields. Some patients may have died after leaving the hospital system and been lost to follow-up. The authors note the sample size may explain why admission bed mobility was not significant in a multivariate analysis. Bed mobility has not been tested prospectively as a standalone tool.

The study was supported by the National Institute of Arthritis and Musculoskeletal and Skin Diseases and The H Foundation. One author reports research funding from Gilead Sciences.

Do not use a low bed mobility score to decide that a patient will not survive or to deny rehabilitation. Patients received tumor surgery, radiotherapy, chemotherapy, sometimes tumor-treating fields, and inpatient rehabilitation together, so bed mobility was not shown to change survival on its own. This was a retrospective single-site prognostic association, not a tested prediction model.